Shares of Insight Molecular Diagnostics Inc. (NASDAQ:IMDX – Get Free Report) have received a consensus rating of “Hold” from the five ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $5.75.
A number of research analysts recently issued reports on IMDX shares. Wall Street Zen upgraded shares of Insight Molecular Diagnostics from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insight Molecular Diagnostics in a report on Monday, September 21st. Stephens reiterated an “equal weight” rating and set a $4.00 target price on shares of Insight Molecular Diagnostics in a research report on Wednesday. BTIG Research reissued a “neutral” rating and issued a $1.00 price target on shares of Insight Molecular Diagnostics in a research report on Wednesday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $9.00 price target on shares of Insight Molecular Diagnostics in a research note on Tuesday, August 18th.
Get Our Latest Research Report on Insight Molecular Diagnostics
Insider Buying and Selling
Insight Molecular Diagnostics Stock Up 17.5%
IMDX opened at $1.95 on Thursday. The stock has a market cap of $63.88 million, a price-to-earnings ratio of -1.56 and a beta of 1.90. The business has a 50 day moving average of $3.05 and a 200-day moving average of $4.43. Insight Molecular Diagnostics has a 12-month low of $1.50 and a 12-month high of $7.51.
Insight Molecular Diagnostics (NASDAQ:IMDX – Get Free Report) last posted its quarterly earnings data on Monday, November 16th. The company reported ($0.19) EPS for the quarter. The business had revenue of $0.56 million during the quarter.
About Insight Molecular Diagnostics
Oncocyte Corporation, now known as Insight Molecular Diagnostics, Inc. (NASDAQ: IMDX), is a molecular diagnostics company focused on monitoring organ transplants. Its tests analyze donor-derived cell-free DNA in a transplant recipient’s blood to help assess graft health and identify signs of potential injury or rejection. The company’s VitaGraft tests include assays for kidney and liver transplant monitoring. These laboratory-developed tests are processed through the company’s clinical laboratory and are intended to provide clinicians with information that can complement other aspects of post-transplant care.
Recommended Stories
- Five stocks we like better than Insight Molecular Diagnostics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Insight Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insight Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
